bioAffinity Technologies, Inc. (BIAF)
USD 0.51
(9.09%)
USD 0.51
(9.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.97 Million USD | -98.78% |
| 2022 | -4.01 Million USD | -81.76% |
| 2021 | -2.2 Million USD | 15.27% |
| 2020 | -2.6 Million USD | 15.78% |
| 2019 | -3.09 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.08 Million USD | -7.33% |
| 2024 Q1 | -1.94 Million USD | 16.96% |
| 2023 Q2 | -1.77 Million USD | -14.15% |
| 2023 FY | -7.97 Million USD | -98.78% |
| 2023 Q4 | -2.34 Million USD | -2.09% |
| 2023 Q3 | -2.29 Million USD | -29.02% |
| 2023 Q1 | -1.55 Million USD | 4.05% |
| 2022 Q2 | 311.21 Thousand USD | 142.81% |
| 2022 Q1 | -727.04 Thousand USD | -10.2% |
| 2022 FY | -4.01 Million USD | -81.76% |
| 2022 Q4 | -1.62 Million USD | -66.34% |
| 2022 Q3 | -976.15 Thousand USD | -413.66% |
| 2021 Q3 | -526.29 Thousand USD | 0.62% |
| 2021 FY | -2.2 Million USD | 15.27% |
| 2021 Q4 | -659.75 Thousand USD | -25.36% |
| 2021 Q1 | -491.2 Thousand USD | 38.73% |
| 2021 Q2 | -529.56 Thousand USD | -7.81% |
| 2020 FY | -2.6 Million USD | 15.78% |
| 2020 Q4 | -801.71 Thousand USD | 0.0% |
| 2019 FY | -3.09 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 91.81% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 27.207% |
| Aspira Women's Health Inc. | -18.85 Million USD | 57.706% |
| Biodesix, Inc. | -41.34 Million USD | 80.714% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -207.421% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -0.0% |
| Bionano Genomics, Inc. | -215.24 Million USD | 96.296% |
| CareDx, Inc | -101.9 Million USD | 92.175% |
| Check-Cap Ltd. | -19.28 Million USD | 58.66% |
| Castle Biosciences, Inc. | -67.97 Million USD | 88.271% |
| DarioHealth Corp. | -56.18 Million USD | 85.81% |
| Exact Sciences Corporation | -215.01 Million USD | 96.292% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 89.032% |
| Guardant Health, Inc. | -564.72 Million USD | 98.588% |
| ICON Public Limited Company | 956.15 Million USD | 100.834% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.727% |
| Illumina, Inc. | -1.06 Billion USD | 99.254% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 22.463% |
| iSpecimen Inc. | -11.16 Million USD | 28.615% |
| Standard BioTools Inc. | -76.6 Million USD | 89.591% |
| MDxHealth SA | -27.32 Million USD | 70.823% |
| 23andMe Holding Co. | -321.35 Million USD | 97.519% |
| Medpace Holdings, Inc. | 336.82 Million USD | 102.367% |
| Myriad Genetics, Inc. | -123.7 Million USD | 93.554% |
| Mainz Biomed B.V. | -26.64 Million USD | 70.076% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 24.214% |
| NeoGenomics, Inc. | -107.73 Million USD | 92.599% |
| Neogen Corporation | 58.66 Million USD | 113.592% |
| Inotiv, Inc. | -81.46 Million USD | 90.212% |
| Natera, Inc. | -446.24 Million USD | 98.213% |
| OpGen, Inc. | -15.68 Million USD | 49.178% |
| OPKO Health, Inc. | -157.02 Million USD | 94.922% |
| Psychemedics Corporation | -2.92 Million USD | -172.962% |
| Prenetics Global Limited | -52.51 Million USD | 84.817% |
| Prenetics Global Limited | -52.51 Million USD | 84.817% |
| Precipio, Inc. | -7.62 Million USD | -4.636% |
| Personalis, Inc. | -109.93 Million USD | 92.747% |
| RadNet, Inc. | 98.69 Million USD | 108.078% |
| Sera Prognostics, Inc. | -39.82 Million USD | 79.977% |
| Sotera Health Company | 276.69 Million USD | 102.882% |
| Neuronetics, Inc. | -30.55 Million USD | 73.904% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -83.461% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -83.461% |
| Trinity Biotech plc | -27.04 Million USD | 70.519% |
| T2 Biosystems, Inc. | -49.66 Million USD | 83.946% |
| Twist Bioscience Corporation | -220.83 Million USD | 96.389% |
| Exagen Inc. | -22.83 Million USD | 65.086% |